Perioperative immunotherapy: the main clinical treatment for resectable non-small cell lung cancer.

Yuan, Zhijun; Yang, Mengyuan; Zhong, Xian

Yuan, Zhijun; Yang, Mengyuan; Zhong, Xian.

Afiliación

Yuan Z; Department of Radiation Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang Ch
Yang M; Department of Medical Oncology, The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China.
Zhong X; Zhejiang Provincial Clinical Research Center for CANCER Hangzhou Zhejiang China.

MedComm (2020) ; 5(3): e498, 2024 Mar.

Article en En | MEDLINE | ID: mdl-38420164

ABSTRACT

ABSTRACT

Phase 3 clinical trials of perioperative immunotherapy for resectable non-small cell lung cancer (NSCLC) In recent years, immunotherapy for NSCLC is not only limited to advanced disease, but also has shown gratifying efficacy for early resectable NSCLC. With the publication of the results of several phase 3 clinical trials, perioperative immunotherapy will become one of the main treatment modalities for resectable NSCLC.

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: MedComm (2020) Año: 2024 Tipo del documento: Article Pais de publicación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google